Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of
Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive
Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.